Cash totaled $3.9 million at June 30, 2026, with operating cash outflow of approximately $6.0 million during the quarter.
Pivot won FDA clearance on April 9, 2026; commercial availability was announced in June 2026 with initial shipments underway.
Quarterly loss and expense trends
Modular Medical posted a net loss of approximately $6.5 million for the three months ended June 30, 2026.
Research and development expense fell 14.9% to $4.37 million, on lower personnel, stock-based compensation, consulting, and material costs.
Selling, general and administrative expense rose 29.8% to $2.17 million, on higher sales and marketing, professional services, and investor relations fees.
MODD•
